{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:26:11Z","timestamp":1791595571556,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the cell-killing effects of neutron capture-enhanced particle therapy (NCEPT) outside the proton beam irradiation (PBI) field.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Human osteosarcoma cells (MG63) were divided into control and NCEPT groups. Four hours before irradiation, the NCEPT group was exposed to <jats:sup>10<\/jats:sup>B-boronophenylalanine. PBI was performed by targeting a gel bolus, with tissue culture plates placed outside the PBI field adjacent to the gel bolus. The bolus was irradiated with 12, 36, or 72\u00a0Gy. Cell survival fractions were calculated for wells adjacent to the bolus. Furthermore, the neutron fluence generated by PBI in the tissue culture plates was calculated using a Monte Carlo simulation. After 12, 36, and 72\u00a0Gy bolus irradiation, the cell survival rates in the control group were 103%, 95%, and 95%, respectively, whereas those in the NCEPT group were 84%, 75%, and 51%, respectively. The cell survival fraction in the NCEPT group was significantly lower than that in the control group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The mean neutron fluence in the wells adjacent to the bolus was 1.24\u2009\u00d7\u200910<jats:sup>8<\/jats:sup> (1\/cm<jats:sup>2<\/jats:sup>) at 72\u00a0Gy irradiation. Although NCEPT enhanced cell-killing outside the PBI field, the magnitude of this effect was modest.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13104-025-07362-5","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:31:28Z","timestamp":1752593488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutron capture-enhanced proton beam therapy outside the irradiation field: in vitro experiments"],"prefix":"10.1186","volume":"18","author":[{"given":"Shintaro","family":"Shiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tokuuye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"7362_CR1","doi-asserted-by":"publisher","unstructured":"Paganetti H. Proton beam therapy. IOP Publishing; 2016. https:\/\/doi.org\/10.1088\/978-0-7503-1370-4.","DOI":"10.1088\/978-0-7503-1370-4"},{"key":"7362_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","volume":"101","author":"C Nantavithya","year":"2018","unstructured":"Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;101:558\u201363. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.022.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7362_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11912-020-0889-9","volume":"22","author":"O Siddiqui","year":"2020","unstructured":"Siddiqui O, Pollock A, Samanta S, Kaiser A, Molitoris JK. Proton beam therapy in liver malignancies. Curr Oncol Rep. 2020;22:30. https:\/\/doi.org\/10.1007\/s11912-020-0889-9.","journal-title":"Curr Oncol Rep"},{"key":"7362_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijrobp.2010.06.024","volume":"81","author":"H Nakayama","year":"2011","unstructured":"Nakayama H, Satoh H, Sugahara S, Kurishima K, Tsuboi K, Sakurai H, et al. Proton beam therapy of stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:979\u201384. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.024.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7362_CR5","doi-asserted-by":"publisher","first-page":"e172032","DOI":"10.1001\/jamaoncol.2017.2032","volume":"3","author":"JY Chang","year":"2017","unstructured":"Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3:e172032. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2032.","journal-title":"JAMA Oncol"},{"key":"7362_CR6","doi-asserted-by":"publisher","first-page":"16257","DOI":"10.1038\/s41598-018-34643-w","volume":"8","author":"M Safavi-Naeini","year":"2018","unstructured":"Safavi-Naeini M, Chacon A, Guatelli S, Franklin DR, Bambery K, Gregoire MC, et al. Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons. Sci Rep. 2018;8:16257. https:\/\/doi.org\/10.1038\/s41598-018-34643-w.","journal-title":"Sci Rep"},{"key":"7362_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cas.12602","volume":"106","author":"P Wongthai","year":"2015","unstructured":"Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, et al. Boronophenylalanine, a Boron delivery agent for Boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106:279\u201386. https:\/\/doi.org\/10.1111\/cas.12602.","journal-title":"Cancer Sci"},{"key":"7362_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/2193-1801-3-128","volume":"3","author":"SI Masunaga","year":"2014","unstructured":"Masunaga SI, Sakurai Y, Tanaka H, Tano K, Suzuki M, Kondo N, et al. The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in Boron neutron capture therapy. Springerplus. 2014;3:128. https:\/\/doi.org\/10.1186\/2193-1801-3-128.","journal-title":"Springerplus"},{"key":"7362_CR9","doi-asserted-by":"publisher","first-page":"28484","DOI":"10.1038\/s41598-024-79045-3","volume":"14","author":"S Shiba","year":"2024","unstructured":"Shiba S, Shimo T, Yamanaka M, Yagihashi T, Sakai M, Ohno T, et al. Increased cell killing effect in neutron capture enhanced proton beam therapy. Sci Rep. 2024;14:28484. https:\/\/doi.org\/10.1038\/s41598-024-79045-3.","journal-title":"Sci Rep"},{"key":"7362_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijrobp.2024.02.052","volume":"120","author":"N Howell","year":"2024","unstructured":"Howell N, Middleton RJ, Sierro F, Fraser BH, Wyatt NA, Chacon A, et al. Neutron capture enhances dose and reduces cancer cell viability in and out of beam during helium and carbon ion therapy. Int J Radiat Oncol Biol Phys. 2024;120:229\u201342. S0360-3016(24)00368-7.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7362_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/00223131.2023.2275736","volume":"61","author":"T Sato","year":"2024","unstructured":"Sato T, Iwamoto Y, Hashimoto S, Ogawa T, Furuta T, Abe SI, et al. Recent improvements of the particle and heavy ion transport code System\u2013PHITS version 3.33. J Nucl Sci Technol. 2024;61:127\u201335. https:\/\/doi.org\/10.1080\/00223131.2023.2275736.","journal-title":"J Nucl Sci Technol"},{"key":"7362_CR12","doi-asserted-by":"publisher","first-page":"110187","DOI":"10.1016\/j.apradiso.2022.110187","volume":"184","author":"AH Alinejad","year":"2022","unstructured":"Alinejad AH, Kakavand T, Aboudzadeh Rovais MRA, Kakaei S. Study of the 199Au nanoparticles production parameters via irradiation of platinum target by using thermal neutrons. Appl Radiat Isot. 2022;184:110187. https:\/\/doi.org\/10.1016\/j.apradiso.2022.110187.","journal-title":"Appl Radiat Isot"},{"key":"7362_CR13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.21873\/invivo.13175","volume":"37","author":"S Shiba","year":"2023","unstructured":"Shiba S, Yamanaka M, Matsumoto K, Yamano A, Shimo T, Suzuki S, et al. Relative biological effectiveness values of spot-scanning proton beam therapy at Shonan Kamakura general hospital. Vivo. 2023;37:1016\u201321. https:\/\/doi.org\/10.21873\/invivo.13175.","journal-title":"Vivo"},{"key":"7362_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hed.20418","volume":"28","author":"T Aihara","year":"2006","unstructured":"Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First clinical case of Boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck. 2006;28:850\u20135. https:\/\/doi.org\/10.1002\/hed.20418.","journal-title":"Head Neck"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07362-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07362-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07362-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:03:54Z","timestamp":1757243034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-025-07362-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7362"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07362-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this study was an in vitro experiments using only commercially available cell lines and did not use any patient-related information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Boronophenylalanine was provided by Stella Pharma Corporation (Japan). Tatsuya Ohno received funding from Hitachi. The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Boronophenylalanine was provided by Stella Pharma Corporation (Japan). Tatsuya Ohno received funding from Hitachi. The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received no external funding.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}}],"article-number":"297"}}